1-1 of 1
Chris Dvergsten
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes

Klara R. Klein, Jennifer L.R. Freeman, Imogene Dunn, Chris Dvergsten, M. Sue Kirkman, John B. Buse, Carmen Valcarce, SimpliciT1 research group, John B. Buse, Klara R. Klein, M. Sue Kirkman, Katherine A. Bergamo, Elizabeth H. Harris, Jean M. Dostou, Laura A. Young, Sriram Machineni, Alex M. Kass, Jamie C. Diner, Milana Dezube, Virginia C. Purrington, Julie M. Uehling, Rachael M. Fraser, Katherine R. Schuch, Jennifer V. Rowell, Ali Qamar, K. Jean Lucas, Luke Snedaker, Stephanie Hoover, Justin Smith, Paul Becton, Jeffrey Hainsworth, Timothy S. Bailey, Juan Pablo Garcia-Naranjo, Niki Nguyen, Bruce W. Bode, Jennifer M. Boyd, Betsy Childs, Pablo Mora, Allison Camacho, Carl D. Vance, Karen Lugo, Anuj Bhargava, Kirstie Stifel, Lisa B. Connery, Birjis Khan, Simone D. Smith, John Parker, Kathryn Zweier, Emily Kronenfeld, Brittany Savoca, Viral N. Shah, Prakriti Joshee, Shivani Dixit, Hal Joseph, Halis Kaan Akturk, Subbulaxami Trikudanathan, Dori Khakpour, Julia Chang, Anne Peters, Pejman Cohan, Mark Harmel, Wendy S . Lane
Journal: Diabetes Care
Diabetes Care 2021;44(4):960–968
https://doi.org/10.2337/dc20-2684
Published: 23 February 2021
View article titled, The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes
Open the PDF for The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes in another window